FDA accepts Xspray Pharma’s NDA resubmission for Dasynoc

Xspray Pharma

12 February 2024 -  The US FDA has accepted the resubmission of Xspray Pharma’s new drug application for Dasynoc, following a complete response letter where additional information was requested. 

The FDA has now assigned a Prescription Drug User Fee Act date to 31July  2024.

Read Xspray Pharma press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , US , Dossier